Back

Tricuspid regurgitation disease stages and treatment outcomes after transcatheter tricuspid valve repair

12 May 2024 (13:45 - 14:00)
Organised by: Logo
Congress Presentation Part of: Young Investigator Award (YIA) Clinical Cardiology Intervention HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Florian Schlotter

University Medical Centre of the Johannes Gutenberg University, Mainz (Germany)

3 More presentations in this session

Presentation thumbnail
Heart Failure and autoimmune disease: a Nationwide Cohort Study
Ms G. Sun (Guangzhou, CN)
Abstract Slides Video
Presentation thumbnail
Can SGLT2i use decrease the risk of atrial fibrillation in patients with heart failure with reduced ejection fraction: a retrospective cohort study
Doctor J. Alejandro (Baltimore, US)
Abstract Slides Video
Presentation thumbnail
Effects of dapagliflozin on new-onset diabetes in patients with heart failure: a pooled, participant-level analysis of the DAPA-HF and DELIVER trials
Doctor M. Lassen (Copenhagen, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Young Investigator Award (YIA) Clinical Cardiology
Video

The Event

Event poster

Heart Failure 2024

12 May 2024 13:45 CET
You may be interested in
thumbnail
Congress Presentation
TRISCEND II trial: TTVR outcomes by baseline TR severity
thumbnail
Congress Presentation
Repairing the tricuspid valve in heart failure: is it beneficial?
thumbnail
Congress Presentation
What is the evidence for TEER in tricuspid regurgitation?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources